Day 1 :
Keynote Forum
Dr. Ofir Aharon
CEO and Founder of Patternox Ltd
Keynote: Differential optical-polarimetry to detect skin distortion and skin cancer
Time : 10:00-10:40
Biography:
Dr. Ofir Aharon, CEO and Founder of Patternox Ltd, inventor of PatScope Scanner. Ph.D. in electro-optics engineering, specializing in the field of computational electromagnetism. Worked at the GSI, the particle accelerator in Darmstadt, Germany. Ofir was part of a research team at the CTO Department of Elbit systems, and later had a position at the Advance Development Group as part of the CTO of KLA-Tencor USA. He is also the inventor of optical devices such as the DOSI scanner. He was Meopta’s representative and mediator in Samsung’s CTO and LG’s CTO-Korea headquarters.
Abstract:
PatScope by Patternox ltd. is a novel approach to detecting potential or actual melanoma that has proven highly effective in clinical trials. The technology identifies undetectable lesion distortions, not fully identified today by dermoscopy and provides an indication to the degree of lesion distortion and the possibility of it being cancerous. Using PatScope Dr. Aharon achieved very high Sensitivity and Specificity. One can only imagine how beneficial Pat Scope can be in the hands of a trained dermatologist.
In clinical tests, using Dr. Aharon’s method, it was identified that all lesions proven malignant by histology, including lesions that were clinically & dermoscopically diagnosed as benign by the medical staff. Pat Scope’s technology enables the detection of tissue structure distortions of skin lesions even with non-pigmented lesions. Such distortions can indicate early stages of skin cancers like Melanoma, BCC and SCC, and early/effective detection results in reduced mortality rate, prevention of unnecessary surgeries and avoiding unnecessary scarring and costs.
Keynote Forum
Dr. John M. Armstrong
Galderma SA, La Tour-De-Peilz, Switzerland
Keynote: GALDERMA – Staying competitive in dermatology drug R&D in a world where disease knowledge and technology development are evolving rapidly
Time : 10: 40-11: 20
Biography:
John M. Armstrong is the Head of Discovery for Galderma’s Prescription business. With a PhD in immunology and post-doctoral fellowships in personalized medicine and signal transduction pathways, he has 33 years of experience in immunology. His experience includes Medical Affairs activities in big pharma and running a personalized medicine company for many years. In his current role, Dr. Armstrong oversees the teams and talents from both Research and Business Development, with the purpose of exploring, discovering, and developing internal innovation, as well as exploring, forming, and managing alliances that bring external innovation into Galderma’s prescription pipeline and product portfolio.
Abstract:
Large biotech companies with a dermatology department generally harbor skills in large molecule development (i.e., monoclonal antibodies / mAbs) but never meet more than 20% of practicing dermatologists globally as a result. In contrast and by nature, dermatology start-up companies come to life with a product or products generated from a unique technology base that reflects either mAb or small molecular entity (SME) expertise; they may succeed by being acquired or by taking a long time to evolve. Historically, legacy pure dermatology players have started with similar limitations, but staying competitive has required them to add a new technology capability to their in-house expertise through either time- and resource-consuming FTE growth or M&A activity, and there are few such legacy derm companies remaining in the world. At Galderma, we have developed a new model for conducting dermatology research – one that allows us to: 1) address any unmet medical need with the most suitable technology required without waiting to grow in-house expertise or finance M&A; 2) double the resources we can invest in new projects; and 3) maintain our service to dermatologists throughout the world – whether they focus on mild disorders or the most severe, life-threatening diseases known in dermatology. In a world where disease knowledge and technology development are evolving at a pace at which others struggle to keep up, Galderma has found a way to ensure that the manufacturer need never be the rate-limiting step in bringing leading edge solutions to the prevention, treatment, or cure of dermatologic disorders.
Keynote Forum
Prof. Bill Cham
Professor, Australasian Institute of Medical Research, Republic of Vanuatu
Keynote: CURADERM : The undaunted new kid on the block for treating skin cancer
Time : 10: 40-11: 20
Biography:
Published more than 120 papers in refereed journals and is serving as an editorial board member of various reputable journals.
Abstract:
The incidence of skin cancer is higher than all other cancers combined and the rate of skin cancer is increasing more than any of the top ten cancers in man. Dermatologists, surgeons, oncologists and radiotherapists usually jointly manage skin cancers. The strengths and limitations of the established procedures are known. The cost for bringing a new anticancer drug to the market is about US$1B. This translates to the ranking of anticancer drugs as the first of global spending by therapeutic class, this is a challenge for the health care system and for those affected by cancer.
Curaderm, a naturally derived topical cream for the treatment of skin cancer, has over the last decades modestly shown to be a very safe and effective treatment with many more strengths than limitations when compared to other skin cancer therapies. Curaderm contains a class of antineoplastic glycoalkaloids, known as solasodine rhamnosides (BEC). This review presents the developmental stages of Research, Preclinical and Clinical (Phases I to IV) of the topical cream Curaderm. Cytotoxic BEC drugs offer not only gains in specificity and efficacy, but also in safety, tolerability, non-resistance, convenience and affordability in the treatment of patients with skin cancer.
- Skin care | Laser Treatment | Dermatopathology | Dermatoscopy | Clinical Dermatology
Location: Prague, Czech Republic
Session Introduction
Dr. Gaston Cornu Labat
Professor, Australasian Institute of Medical Research, Australia.
Title: Solasodine Rhamnosyl Glycosides, a simple, safe and highly effective treatment for Actinic Keratosis
Time : 12:00-13:00
Biography:
Gaston Cornu Labat graduated as a Medical Doctor from the University of Buenos Aires in 1991. He is in private practice in the USA since 1994 in General and Oncologic Surgery and Integrative Medicine. He is a Medical Advisor for the Australasian Institute of Medical Research in Brisbane, Australia.
Bill Elliot Cham is Head of Australasian Institute of Medical Research and independent reviewer for numerous science journals, Diplomate in Chemistry from The Netherlands in 1967, Doctor in Biochemistry and PhD in Medicine from the University of Brisbane in 1975 and 1982
Abstract:
Actinic keratosis (AK) is a highly prevalent skin lesion worldwide with malignant potential. The incidence of this disease correlates with fair skin tone and cumulative sun exposure. Current standards of care include various topical treatments with variable efficacy and safety, photodynamic therapy and surgical excision as the most common therapeutic approaches.
Solasodine rhamnosyl glycosides (SRGs) represent a group of mono, di, and triglycosides naturally occurring in plants of the Solanaceae family, genus solanum. Formulated as a cream for topical application, they have been in use worldwide for the treatment of AK, keratoacanthomas, BCC and SCC worldwide for over three decades.
SRGs represent a little known, simple, and highly safe and effective treatment for AK. The authors present a review of the published clinical trials and scientific work, and 33 years of clinical experience in the use of topical SRGs in the treatment of AK; their mechanism of action, safety and effectiveness profile, and a comparison to published data on the current standards of care are reviewed.
Ms. Duaa Abdulmohsen
Salmaneya Medical Complex, Manama. Bahrain
Title: Treatment of Nevus of Ota with 694 nm Q-Switched Ruby Laser.
Biography:
Dr Duaa has completed her Master’s degree in Clinical Dermatology with distinction from Cardiff University, United Kingdom in 2017. She is currently a Dermatology Resident in Salmaneya Medical Complex due to complete her Arab Board Dermatology and Venerology Residency Training program in 2020
Abstract:
A 24 years old female with Fitzpatrick type III skin presented to Aesthetica Clinic Dubai with unilateral periorbital hyperpigmentation macule present since birth. The diagnosis of the Nevus of Ota was made through the detailed history and the thorough examination. There were no similar condition anywhere else in her body and the family history is irrelevant. The Patient was photographed before the beginning of the sessions and after. Full explanation of the treatment plan with SINON Q- switched Ruby laser (QSRL) was done. A written informed consent was signed and a topical anesthesia was applied for 30 to 60 minutes under occlusion prior the laser treatment. Post procedure, sunscreen and topical antibiotic along with topical steroid, emollient, Melanin control mask and eldoquine 4% were prescribed in between sessions. The patient had 7 sessions, two months apart, allowing the healing process to complete. There was no significant side effect as persistent erythema or scarring although the patient mentioned that she experienced minor pain sensation during the procedure. The parameters used with the SINON Q-switched Ruby laser (QSRL) were 3j/cm2 with the blue tip one pass with no overlap all over the hyperpigmented areas. Frosting was present with no elevation. The results were evaluated based on visual inspection, patient satisfaction and comparing before and after photos. The patient was completely satisfied and this affected her quality of life as well as her self- esteem
Dr. Keshvad hedayatyanfard
Shahid Beheshti University of Medical Sciences, Iran
Title: Chitosan/PVA/Doxycycline film and nanofiber accelerate diabetic wound healing in a Rat model
Biography:
Keshvad hedayatyanfard has completed his PhD from Shahid Beheshti University of Medical Sciences. His research interest is focused on the acute and chronic wound healing, hypertrophic scar/keloid, and autoimmune disease management. He also was nominated as the holder of TOP invention certificate at inventions festival of Iran's national elite's foundation (2015, 2016). Currently, he works in Alborz University of Medical Sciences.
Abstract:
In this study we evaluated the effects of nanofiber and film polymers with doxycycline for treating wound in a diabetic rat model. 108 male rats were divided into six groups, the control group, the diabetic control, and the groups were diabetic rats receiving different wound dressing. At the 3rd, 7th, and 14th days, macroscopic/histologic imaging and tissue sampling was performed. Tissues were analyzed for IL-1β, TNF-α, IL-10, TIMP-1, and MMP-2 by using ELISA. Dressings of chitosan, PVA and doxycycline increased the rate of wound closure, the volume of collagen, dermal, and epidermis; in addition it increased the number of fibroblasts and basal cell epidermis cells, vascular length, and decreased the number of neutrophil cells. Inflammatory cytokines and MMP-2 were decreased, and anti-inflammatory IL-10 and TIMP-1 were increased. It was ultimately attained that the combination of chitosan/PVA/doxycycline could be a useful dressing for the healing of diabetic wounds.
Dr. Kiticharoensak Ornrapee
Cardiff University School of Medicine, UK
Title: A Review of the Efficacy and Safety of Retinoids in the Treatment of Ultraviolet Related Skin Conditions and Skin Ageing
Biography:
Abstract:
Dr. Feizollah Niazi
Professor, Department of Plastic and Reconstructive Surgery
Title: Increasing the Histamine Level in Keloid Tissue
Biography:
Dr. Feizollah Niazi is faculty member of Department of Plastic and Reconstructive Surgery, Modarres Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. His resecah interest focused on wound healing, treatment of scar and keloid.
Abstract:
Keloid and hypertrophic scars (HTS) results from an imbalance in production and destruction of collagen during wound healing with an unknown underlying pathophysiological mechanism. This study was designed to evaluate the histamine amount in the keloid and hypertrophic scars, and compared the results with normal skin. This pilot study included 36 participants aged from 18 to 70 years old with keloid (n=), HTS (n=13), or normal (n=12) skin. The amount of histamine in the skin samples was measured with enzyme-linked immunosorbent assay (ELISA). The results showed that the histamine level in keloid samples was significantly higher than in the normal (p=0.0012) or HTS (p=0.0028) groups. However, there was no significant difference between the normal and HTS samples (p=0.92). The increased histamine level in the keloid tissue may contribute to its pathogenesis and application of anti-histamines could be of benefit for the prevention and treatment of keloids.
Dr. Yoav Gronovich
Shaare-Zedek Medical Center, Israel
Title: Improvement of facial scars using autologous fat graft and 1540nm non-ablative erbium laser
Biography:
Dr Gronovich is the head of the Plastic Surgery Department at the Shaare Zedek Medical Center in Jerusalem. He received his medical degree from the Hebrew University in Jerusalem, and completed his residency in Plastic Surgery at the Shaare Zedek Medical Center in Jerusalem. He has been actively involved in research, including more than 20 publications, oral presentations and abstracts. His interests include aesthetic and reconstructive surgery of the face, breast and body, and advanced treatments of scars
Abstract:
Facial scars are a devastating problem both aesthetic and functional. Many treatments have been proposed for improvement of scars. Among the advanced treatments are the use of non-ablative laser which facilitate the synthesis and deposition of collagen in the dermis. Other advanced treatments include fat grafting. This method helps to reshape the scar by volumetric effect of the fat cells, and improve its contour by the adipose derived stem cells that accompany the fat transfer.
Purpose:
We present our experience with 20 consecutive cases of facial scars using fat grafting and resurfacing with 1540 nm non-ablative erbium laser. We wish to emphasize the main advantages of this treatment combination.
Methods and materials:
We began using this combination of treatment in January, 2014, since when twenty patients (8 females, 12 males), median age 42 years (range 16-59) were treated for facial scars using autologous fat graft and non-ablative 1540nm erbium laser. The causes of the scars included trauma (73%) and acne. Two thirds of the scars were new (less than 30 days old). In all of the cases treatment included fat injection to the surface of the scar, using Coleman technique, and a series of five treatments of 1540nm erbium laser (ICON TM Cynosure; Westford, MA, USA) beginning a month later. Patients were evaluated both before and after each treatment, and a follow up of six months was done.
Results:
In all of the cases, the treatment was uneventful with no side effects. The scars were improved both in texture and appearance. Patient satisfaction was high in all of the cases.
Conclusion:
The combination of autologous fat grafting with fractional non ablative laser for scars is a safe and efficient treatment that improves scar appearance and texture.
Biography:
Munirah T. Aljaser has recieved her bachelor of medical sciences (B.Med.Sc.) and Bachelor of Medicine and Surgery (B.M.,B.Ch.) from Kuwait University. She is currently working as a physician at Al-Farwaniya Hospital, dermatology department.
Abstract:
Pustular psoriasis of pregnancy (PPP) is a rare dermatological disease associated with potentially life-threatening maternal and fetal outcomes. We report a case of a 25-year-old primigravida Arabian woman diagnosed with PPP at 36 weeks of gestation, presenting initially as generalized erythematous plaques. Early recognition and treatment with Prednisolone, induction of labor, and later with the addition of cyclosporine, we were able to avoid the complications related to PPP. Given the prognosis of untreated PPP is it imperative to standardize the method of diagnosing and treating the disease to ensure the best possible outcomes for both the mother and the fetus.
Dr. Shaker Yehia Shaker Ibrahim
Minia University faculty of Medicine, Egypt
Title: Abdominoplasty after pregnancy: Current practical controversies
Biography:
Dr. Shaker Yehia Shaker Ibrahim, he graduated in 2008 from faculty of midicine at minia universty he completed my master degree in plastic surgery under title : “5mm safety margin in B.C.C” he is working in my own clinic “S.H.E clinic” and performed alot of plastic surgery and he is interested especialy in abdominoplasty surgery recently my major areas of experiance are laser feild and teaching courses.
Abstract:
Frequently, abdominoplasty is done after women complete childbearing. The main indications for abdominoplasty include: abdominal skin excess, striae, and musculofascial laxity. There are many techniques of abdominoplasty including: standard wide undermining and vertical plication of the rectus fascia with liposuction of the flanks, abdominoplasty with liposuction of the abdomen and minimal midline undermining, abdominoplasty with removal of deep fat from the upper abdomen, circumferential abdominoplasty, and mini-abdominoplasty. Currently, abdominoplasty is the sixth most common cosmetic procedure; however, a controversy remains regarding indications of abdominoplasty, proper preoperative preparation, choice of the appropriate surgical technique, choice between limited and full dissection abdominoplasty, operative techniques for proper positioning of umbilicus and scar, postopertaive management, and strategies to prevent postoperrative complications. Herein, we try to highlight the current practical controversies regarding preoperative, intraoperative, and postoperative management during abdominoplasty after pregnancy.
Dr. Hanan Osman-Ponchet
Founder and CEO at PKDERM Laboratories, France
Title: Title : Effect of Inflammation on the expression of ABC Transporters in Normal Human Keratinocytes
Biography:
Dr. Hanan Osman-Ponchet is currently Founder and CEO at PKDERM Laboratories. PKDERM provides innovative in vitro solutions to pharmaceutical and cosmetic industries to evaluate the efficacy and safety of products likely to come into contact with the skin. Hanan has a PhD in Biochemistry, Cellular and Molecular Biology and a long experience at Sanofi and Galderma. She has authored more than 30 peer-reviewed publications and patents and has given invited oral presentations at different scientific conferences.
Abstract:
Skin is the largest organ in the human body and is one of the major targets of air pollution. There is increasing evidence indicating that ATP-binding cassette (ABC) family transporters play an important role in the transdermal absorption of their substrates [1-4]. Exposure of the skin to air pollutants has been associated with inflammation with increasing production of pro-inflammatory cytokines. The connection between inflammation and ABC transporters transcript levels in the skin is not known. This study investigated the effect of inflammation on the expression levels of ABC transporters in normal human keratinocytes (NHK). NHK (Sterlab France) were treated with pro-inflammatory mediator lipopolysaccharide (LPS). mRNA expression of TNF-alpha, CXCL8 (IL-8), ABCB1, ABCC1, ABCC2 and ABCG2 was measured by quantitative real time RT-PCR. Treatment with LPS up-regulated the mRNA expression of TNF-alpha and IL-8, confirming the inflammatory properties of LPS in human keratinocytes. While LPS treatment had no effect on the expression of ABCG2, it increased the expression of ABCC1 and ABCC2 in human keratinocytes. This study clearly shows a connection between inflammation and ABC transporters transcript levels in human keratinocytes. This finding is of great importance and need to be considered in pharmacokinetic evaluation of anti-inflammatory agents when treating inflammatory skin.